Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to a strong-buy rating in a report issued on Thursday,Zacks.com reports.

Other analysts have also recently issued research reports about the stock. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 price objective for the company. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Finally, Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

Shares of REGN stock opened at $756.81 on Thursday. Regeneron Pharmaceuticals has a fifty-two week low of $753.69 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock’s fifty day moving average is $985.21 and its two-hundred day moving average is $1,032.97. The firm has a market capitalization of $83.17 billion, a P/E ratio of 18.73, a PEG ratio of 3.04 and a beta of 0.15.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.48% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC boosted its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $26,000. Finally, Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth $28,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.